Automating chimeric antigen receptor T-cell manufacturing across distinct platforms delivers similar cell quality, phenotype and function.

BACKGROUND AIMS: Manufacturing chimeric antigen receptor (CAR) T cell therapies is complex and costly, and automation holds tremendous promise to improve access to these life-saving treatments.

METHODS

Here, we compared two end-to-end automated CAR T-cell manufacturing platforms, the CliniMACS Prodigy and the Sefia system, using identical reagents, stimulation conditions, culture duration, perfusion rate and donor starting material to assess how platform design affects critical product attributes.

RESULTS

With identical CD4 and CD8 magnetic isolation reagents, both systems produced similar T-cell yields, with exceptionally high purity and comparable phenotype. During culture, total cell yield differed between platforms, reflecting differences in culture volume; however, expansion rate, population doubling time, transduction efficiency and CAR T-cell yield were not significantly different. The resulting CAR T cells also showed comparable phenotype, exhaustion profiles and in vitro tumor-killing activity. These similar outcomes may be explained by shared media perfusion rates and convergent metabolic profiles, because cell-specific glucose consumption and cell-specific lactate production were similar by the end of culture.

CONCLUSIONS

Collectively, these findings show that distinct automated platforms can generate CAR T-cell products with remarkably similar quality and function when process conditions are aligned. More broadly, they highlight the potential of automation and in-line analytics to standardize CAR T cell manufacturing and improve product consistency from cell collection to patient infusion.